These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 19699208)
1. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. Dimasi N; Gao C; Fleming R; Woods RM; Yao XT; Shirinian L; Kiener PA; Wu H J Mol Biol; 2009 Oct; 393(3):672-92. PubMed ID: 19699208 [TBL] [Abstract][Full Text] [Related]
2. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity. Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438 [TBL] [Abstract][Full Text] [Related]
3. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Gu J; Ghayur T Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980 [TBL] [Abstract][Full Text] [Related]
4. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252 [TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Liu XY; Pop LM; Roopenian DC; Ghetie V; Vitetta ES; Smallshaw JE Int Immunopharmacol; 2006 May; 6(5):791-9. PubMed ID: 16546710 [TBL] [Abstract][Full Text] [Related]
6. Molecular engineering and design of therapeutic antibodies. Presta LG Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541 [TBL] [Abstract][Full Text] [Related]
7. Study of antigen-binding properties of bispecific antibodies. Smirnova MB; Dergunova NN; Kizim EA; Massino YuS ; Nikulina VA; Segal OL; Tereshkina EB; Kolyaskina GI; Dmitriev AD Biochemistry (Mosc); 1997 Jan; 62(1):41-8. PubMed ID: 9113728 [TBL] [Abstract][Full Text] [Related]
8. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Presta LG Adv Drug Deliv Rev; 2006 Aug; 58(5-6):640-56. PubMed ID: 16904789 [TBL] [Abstract][Full Text] [Related]
10. Development of a compact anti-BAFF antibody in Escherichia coli. Cao P; Zhang S; Gong Z; Tang X; Cao M; Hu Y Appl Microbiol Biotechnol; 2006 Nov; 73(1):151-7. PubMed ID: 16625393 [TBL] [Abstract][Full Text] [Related]
11. Two and three-dimensional pattern recognition of organized surfaces by specific antibodies. Addadi L; Rubin N; Scheffer L; Ziblat R Acc Chem Res; 2008 Feb; 41(2):254-64. PubMed ID: 18217721 [TBL] [Abstract][Full Text] [Related]
12. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891 [TBL] [Abstract][Full Text] [Related]
14. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Stork R; Müller D; Kontermann RE Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179 [TBL] [Abstract][Full Text] [Related]
15. Production of chimeric heavy-chain antibodies. Zhang J; MacKenzie R; Durocher Y Methods Mol Biol; 2009; 525():323-36, xv. PubMed ID: 19252853 [TBL] [Abstract][Full Text] [Related]
16. [Characterization of a panel of mouse single-chain antibodies against recombinant human interferon beta1b]. Pavlova MV; Nikolaev IuS; Irodov DM; Okunev OV; Kordium VA; Gil'chuk PV Tsitol Genet; 2008; 42(4):3-11. PubMed ID: 19140425 [TBL] [Abstract][Full Text] [Related]
17. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771 [TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of an enhanced GFP-tagged anti-BAFF scFv antibody. Cao M; Cao P; Yan H; Ren F; Lu W; Hu Y; Zhang S Appl Microbiol Biotechnol; 2008 Jun; 79(3):423-31. PubMed ID: 18427805 [TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a specific polyclonal antibody against the mouse serotonin receptor 1A: a state-of-the-art recommendation on how to characterize antibody specificity. Heo S; Lubec G Electrophoresis; 2010 Dec; 31(23-24):3789-96. PubMed ID: 21064142 [TBL] [Abstract][Full Text] [Related]
20. Structural difference in the complement activation site of human IgG1 and IgG3. Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]